Gaurav Goyal, MD
Expert Physician
Rosai Dorfman Disease (RDD)
Dr. Goyal is a hematologist-oncologist with a special interest in histiocytic disorders. He completed medical school at Smt. N.H.L. Municipal Medical College in Ahmedabad, India, in 2011, and then moved to the United States for further training. He completed his internal medicine residency at Creighton University Medical Center in Omaha, Nebraska, in 2016, followed by a fellowship in hematology and oncology at the Mayo Clinic in Rochester, Minnesota, in 2019.
During his fellowship, Dr. Goyal developed a deep interest in histiocytosis and went on to establish the first multidisciplinary Histiocytosis Working Group, dedicated to improving the understanding and care of patients with these rare diseases. This group was later expanded to form the Histio-Care Network, with multi-institution collaborations to advance the practice, education, and research for patients and families affected by histiocytic disorders. His research spans a wide range of topics including the epidemiology, molecular biology, clinical presentation, treatment, and long-term outcomes of histiocytic disorders. He has led the guidelines for the management of Erdheim-Chester disease (ECD) and Adult Langerhans cell Histiocytosis (LCH).
After joining the University of Alabama at Birmingham (UAB) in 2019, Dr. Goyal expanded his focus to include cancer survivorship and long-term outcomes. In 2022, he launched the Histiocytic Disorder Follow-Up Study to better understand the long-term health effects in people living with histiocytosis.
Dr. Goyal’s work has been supported by multiple organizations, including the Histiocytosis Association, AIDS Malignancy Consortium, Leukemia & Lymphoma Society, and the American Cancer Society. He leads national and international collaborations and clinical trials, and holds several leadership roles, including serving as chair of the Hemophagocytic Lymphohistiocytosis (HLH) in Adults and Adult LCH Working Groups under the Histiocyte Society.
